ABSTRACT
INTRODUCTION
Alzheimer's disease (AD) is one of the most relevant health issues at the start of the new millennium. Its prevalence increases exponentially after age 60, with one in every five individuals in the age-group 80 years or older presenting the typical features of the disease (Henderson & Jorm 1998) . AD is associated with high levels of morbidity, mortality, burden of care and socioeconomic costs (Bland 1998; Brookmeyer, Gray & Kawas 1998; Squêtre, Thwaites & Yeardley 1999) . Hence, interventions that delay or prevent the onset of illness are likely to have major consequences for public health (Brookmeyer et al. 1998; Schumock 1998) . For this reason, the focus of recent epidemiological and clinical studies has been to identify risk factors that could be used to design preventive strategies. One such factor is smoking.
A review of 19 case-control studies found that having ever smoked is associated with decreased risk of AD [odds ratio (OR) = 0.64, 95% confidence interval (CI) = 0.54-0.76] (Lee 1994) . This finding was supported by other reviews (Van Duijn et al. 1994) . The apparent risk reduction of AD linked to smoking was attributed to an as yet unclear neuroprotective effect of nicotine and nicotinic drugs (Newhouse, Potter & Levin 1997 ). In contrast, others have argued that the results reported by case-control studies were a consequence of survival bias rather than a true protective effect of smoking (Riggs 1993) . Recent cohort studies seem to indicate that smoking increases the risk of dementia in general and of AD in particular (Ott et al. 1998) . It is important to clarify the direction of the association between smoking and AD, as this is likely to have significant implications for prevention and health promotion. The present systematic review was performed with the aim of addressing this question.
METHOD

Search strategy
Index Medicus (Medline, 1966 -April 2000 and PsycINFO (1984 -April 2000 databases were consulted for the electronic retrieval of references with the following keywords: (1) smoking (explode), (2) tobacco use disorder (explode), (3) tobacco (explode), (4) nicotine (explode), (5) #1 or #2 or #3 or #4, (6) dementia, delirium, amnestic, cognitive disorder (explode), (7) aids dementia complex, (8) dementia (explode), (9) dementia, multi-infarct, (10) dementia, vascular, (11) Alzheimer disease (explode), (12) #6 or #7 or #8 or #9 or #10 or #11, 13. #5 and #12. A total of 126 and 36 references were retrieved from Medline and PsycINFO, respectively. The electronic search was supplemented by manual search of relevant references quoted by other studies and reviews. Titles and abstracts of papers were examined by one of us (OPA) and obviously irrelevant articles were discarded. All other papers were retrieved and examined by at least two of the authors. They were initially assessed for relevance of the exposure (ever having smoked), outcome (Alzheimer's disease), and study design (case-control or cohort study). Reviews, case-series and cross-sectional surveys were excluded from the analysis. Selected papers were rated systematically with a scale designed to assess the quality of study methodology (Appendix 1).
Analysis of data
Raw data were extracted from all but four case-control studies (data not available), and crude odds ratios and confidence intervals were calculated using the Cornfield method. Meta-analysis (fixed-effects model) was then used to estimate the pooled odds ratio (OR) or risk ratio (RR) and 95% confidence limits (95%CI) (see more details about this method in Sutton 2000) . The test for heterogeneity was performed to assess the data included in the analysis. This analysis was repeated twice more for subjects of the case-control studies, including, first, only studies with quality score of at least 26/52 and secondly, only studies employing a matched design and having a score of at least 26/52. The same approach was used for the analysis of cohort studies (quality score ≥ 13/26).
RESULTS
We identified 21 case-control studies that reported data on the association between ever smoking and AD (total number of subjects = 5323). Their results are summarized in Table 1 . The estimated pooled odds ratio was 0.74 & the confidence limits 0.66-0.84 (adjusted or matched OR were used when raw data were not available). The test of heterogeneity produced a p-value of 0.246. A second analysis was conducted including only the eight studies with quality scores ≥ 26. This time, the data were adjusted for confounding variables (such as age, sex, schooling and alcohol use) or, whenever available, those coming from matched analysis. The pooled odds ratio was 0.82 and the confidence limits 0.70-0.97 (Fig. 1) . The p-value for the test of heterogeneity was 0.279. Finally, analysis of the four case-control studies that used a matched design and had a quality score ≥ 26 produced an odds ratio of 0.82 (95% CI = 0.53-1.27) and a p-value for the test of heterogeneity of 0.283. There were only eight cohort studies available for analysis ( Table 2) . One of them (Ott et al. 1998) had been included in a pooled data analysis of four different European cohort studies (Launer et al. 1999) and was, for this reason, excluded from the final analysis. The overall RR of AD among ever smokers was 1.10 (CI = 0.94-1.29) and the p-value for the test of heterogeneity 0.004 (total number of subjects = 43,885). [This number excludes the report by Ott et al. (1998) included in Launer et al. (1999) 's pooled analysis and Hirayama (1992) (the exact number of cases at risk that were followed-up until death was not reported).] Further analysis was performed excluding studies with less than 10 patients with AD who were smokers (Katzman et al. 1989) , or whose description of the diagnosis of AD was unclear (Hirayama 1992) . The report by Hebert et al. (1992) was also excluded from the analysis because only 15.3% of the subjects evaluated for incident AD were derived for certain from their original sample-data from an undisclosed number of older adults taking part in a different study were included in their final sample of 513 subjects. The overall RR (Wang et al. 1997; Launer et al. 1999; Merchant et al. 1999; Doll et al. 2000) was 1.12 (CI = 0.93-1.34), and the p-value for the test of heterogeneity 0.308 (Fig. 2) . Finally, data were pooled from cohort studies that described the number of subjects who were smokers at baseline and later developed AD (Launer et al. 1999; Merchant et al. 1999 )-the RR was 1.99 (CI = 1.33-2.98).
DISCUSSION
Three previous reviews (Graves et al. 1991; Lee 1994; van Duijn et al. 1994 ) based on data from case-control studies indicate that ever smoking is associated with decreased risk of AD. Lee (1994) reported that the relative risk of AD associated with ever smoking was 0.64 (CI = 0.54-0.76), whereas van Duijn et al. (1994) reported a ratio of 0.8 (CI = 0.6-1.0). Similar associations were reported by Graves et al. (1991) . The data from the 21 case-control studies included in our initial analysis produced a pooled OR for AD of 0.74 (95%CI = 0.66-0.84) among ever smokers. The subsequent exclusion of studies considered to have unsatisfactory methodology or sample size led to an increased OR of 0.82 (95% CI = 0.70-0.97). Restricting the analysis even further to studies with a matched design resulted in a nonsignificant OR of 0.82 (CI = 0.53-1.27). The increase in OR values associated with the use of more stringent inclusion criteria suggests that case-control studies are vulnerable to a type of bias that decreases the likelihood of patients with AD who are also smokers being included in the study. It could also indicate a movement towards the null due to retention of studies with greater degrees of random error.
All case-control studies available to date are relatively small-the largest reports data on just over 200 cases (Canadian Study of Health & Aging 1994) . In addition, none of them showed, individually, compelling evidence for a protective effect of smoking, although there was a consistent trend in that direction. This suggests that the
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Figure 1
Summary of selected casecontrol studies looking at the association between ever smoking and Alzheimer's disease (AD). Diamonds (᭜) indicate the odds ratio of developing AD among subjects who were ever smokers in comparison to non-smokers. The horizontal lines indicate the limits of the 95% confidence interval for the odds ratio for each study. lower prevalence of smoking among patients with AD cannot be explained simply by random error. Riggs (1993) suggested that the protective effect of smoking may be due to survival bias. Wang et al. (1999) , for example, found that a history of smoking was associated with increased mortality among patients with dementia (hazard ratio = 3.5, CI = 1.4-8.8), but not controls (hazard ratio = 0.8, CI = 0.5-1.2). Hence, patients with dementia who have been smokers may be eliminated earlier from the population and, as a consequence, would be under-represented in cross-sectional samples. Differential mortality is always likely to be a problem where there is a need to investigate the effects of smoking in a disorder with very low incidence rates before age 75 years, which is the case of Alzheimer's disease (WolfKlein et al. 1988) . Smoking has a robust negative effect on survival. This can be illustrated with data from the work reported by Doll et al. (1994) -they found that 83% of male non-smokers and 60% of the smokers reached the age of 70 years. Similarly, 57% of the non-smokers survived to age 80 years compared with only 26% of the smokers. Hence, cross-sectional studies of prevalent cases with AD are less likely to report the presence of smokers in the sample (French et al. 1985; Amaducci et al. 1986; Barclay & Kheyfets 1989; Graves et al. 1990; van Duijn & Hofman 1991; Forster et al. 1995; van Duijn et al. 1995) . Differential mortality can also distort the results of case-control studies that use incident cases of AD, particularly if matching for age is not stringent.
Bias may also be introduced in case-control studies that select controls from clinical samples (Chandra et al. 1987; Salib & Hillier 1997) . Subjects in contact with medical services are more likely to display smoking health-related problems (e.g. cardiovascular disease, emphysema, stroke, etc.). For this reason, the prevalence of smoking is likely to be high among controls recruited from clinical settings (Morabia, Stellman & Wynder 1996) . There is also a potential problem with the reliability of the diagnosis of AD, particularly in studies that exclude patients with concomitant vascular diseasethis approach is likely to select patients with AD who do not smoke. Finally, the use of carers as the main source of information about the exposure (smoking) is another potential source of error when dealing with a disorder such as AD-carers may not be fully aware of prior history of smoking among patients, and patients may be unable to provide accurate information about their own smoking history.
Genetic factors may also influence the results of case-control studies. For example, Carmelli et al. (1999) investigated the effect of the e4 allele of the apolipoprotein E (APOE4) on the cognitive function of 589 male subjects aged 59-69 years. Smoking was significantly associated with poor cognition (OR = 2.0, CI = 1.2-3.2). Stratification by APOE4 showed that the e4 allele reduces the harmful effect of smoking (although this is still significant)-these results suggest that the effects of environmental variables (such as smoking) on intellectual abilities are less marked when genetic risk factors are present.
Cohort studies should not be subject to selection bias, as long as loss to follow-up is kept to a minimum and 
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Favours non-smoking Figure 2 Summary of selected cohort studies looking at the association between ever smoking and Alzheimer's disease (AD). Diamonds (᭜) indicate the risk ratio of developing AD among subjects who were smokers at the beginning of follow-up in comparison to non-smokers.The horizontal lines indicate the limits of the 95% confidence interval for the risk ratio for each study.
death is used as one of the outcome measures. Cohort studies also avoid the problems of collecting exposure information from a surrogate respondent, as potential cases can be interviewed prior to incidence of disease (which reduces recall bias). The number of cohort studies that are currently available for analysis is relatively small, but their results suggest an association in the opposite direction to that reported by case-control studies: smoking increases the risk of AD. This association is particularly strong when exposure to tobacco is recorded in the most reliable way, i.e. current smoking at the beginning of follow-up (RR = 1.99, CI = 1.33-2.98).
The mechanisms by which smoking would prevent or increase the risk of AD remain unclear. Some speculate that the nicotinic effects of smoking improve cognitive functioning (Jones et al. 1992) , while others suggest that the increased frequency of cardiovascular and cerebrovascular illnesses among smokers (Jee et al. 1999 ) is likely to increase the risk of AD in later life (Ott et al. 1997; Skoog 1998; Esiri et al. 1999) .
In conclusion, the results reported in these metaanalyses show that the direction of the association between smoking and AD remains unclear. Previous claims that smoking reduces the risk of AD can no longer be supported. In fact, the results of recent cohort studies suggest that a history of smoking is associated with an increased incidence of AD-these findings are particularly robust for subjects who were current smokers at the time of enrolment. One obvious limitation, however, is that the number of cohort studies (n = 8) and incident cases available for analysis (n = 1076) is still too small to be used reliably as evidence that smoking increases the risk of AD. It is our view that this issue can only be addressed properly with a large cohort study designed to investigate the effects of smoking on cognitive decline and risk of AD-if its results confirm the trend observed by recent studies (Ott et al. 1998; Launer et al. 1999; Merchant et al. 1999; Wang et al. 1999) , then smoking prevention and cessation should become public health priorities in the fight against AD. 
